Biography
- After completing his training in General Surgery, Dr Contreras-Saldivar executed postdoctoral studies in the areas of transplant immunobiology and vascular biology at Children's Hospital Boston and Harvard Medical School. During that time he received a Fellowship Award in Transplantation from the American Society of Transplant Surgeons. The result of his work has been published in peer review journals and been presented in different national and international forums. He has been honored with a "Young Investigator Award" by the American Society of Transplantation on two consecutive occasions. He completed his fellowship as abdominal transplant surgeon At Mount Sinai Hospital and then joined as a Faculty to the Recanati/Miller Transplantation Institute.
Awards
- 2006
Young Investigator Award.
American Society of Transplantation (AST),- 2007
New award
American Society of Transplantation (AST),2006 - 2008
Fellowship Award in Transplantation
American Society of Transplant Surgeons (ASTS)
Publications
Datta D, Contreras G, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S. Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression.. Journal of the American Society of Nephrology : JASN 2008 Dec; 19(12): 2437-46.
Contreras AG, Dormond O, Edelbauer M, Calzadilla K, Hoerning A, Pal S, Briscoe DM. mTOR-understanding the clinical effects. Transplantation proceedings 2008 Dec; 40(10 Suppl).
Dormond O, Contreras AG, Meijer E, Datta D, Flynn E, Pal S, Briscoe M. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. Journal of immunology (Baltimore, Md. : 1950) 2008 Dec; 181(11).
Datta D, Contreras AG, Basu A, Dormond O, Flynn E, Briscoe DM, Pal S. Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer research 2009 Dec; 69(23).
Basu A, Contreras AG, Datta D, Flynn E, Zeng L, Cohen HT, Briscoe DM, Pal S. Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer research 2008 Jul; 68(14).
Contreras AG, Briscoe DM. Every allograft needs a silver lining. The Journal of clinical investigation 2007 Dec; 117(12).
Medina-Franco H, Contreras-Saldívar A, Ramos-De La Medina A, Palacios-Sanchez P, Cortés-González R, Ugarte JA. Surgery for stage IV gastric cancer. American journal of surgery 2004 Apr; 187(4).
Haskova Z, Izawa A, Contreras AG, Flynn E, Boulday G, Briscoe DM. Organ-specific differences in the function of MCP-1 and CXCR3 during cardiac and skin allograft rejection. Transplantation 2007 Jun; 83(12).
Mercado MA, Chan C, Tielve M, Contreras A, Gálvez-Treviño R, Ramos-Gallardo G, Orozco H. [Iatrogenic injury of the bile duct. Experience with repair in 180 patients]. Revista de gastroenterología de México; 67(4).
Mena-Madrazo JA, Romero-Lagarza P, Terrazas-Solís H, Navarro-Alvarez S, Contreras A, Mercado MA. [Clinical images in gastroenterology. Hydatid cyst]. Revista de gastroenterología de México; 67(2).
Mercado MA, Orozco H, de la Garza L, López-Martínez LM, Contreras A, Guillén-Navarro E. Biliary duct injury: partial segment IV resection for intrahepatic reconstruction of biliary lesions. Archives of surgery (Chicago, Ill. : 1960) 1999 Sep; 134(9).
Mercado MA, Orozco H, Vasquez M, Pantoja JP, Contreras A, Catzin-Kuhlmann A, Flores A, Rodriguez-Davalos M. Comparative study of 2 variants of a modified esophageal transection in the Sugiura-Futagawa operation. Archives of surgery (Chicago, Ill. : 1960) 1998 Oct; 133(10).
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Contreras-Saldivar did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.